Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception
30 nov. 2023 09h45 HE
|
Biostax Corp
Orlando, FL, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biostax Corp., (OTC Pink: BTAX) (“Biostax”), a hub and spoke biotech development engine, proudly announces its participation in the upcoming U.S....
Biostax Announces a Director Appointment of Influential Business Leader Craig Suro
15 nov. 2023 09h30 HE
|
Biostax Corp
Orlando, FL, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Biostax Corp (OTC Pink: BTAX) (“Biostax”), a hub and spoke biotech development engine, announces the appointment of Influential Business Leader Roger...
Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors
02 nov. 2023 10h10 HE
|
Biostax Corp
Orlando, FL, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Biostax Corp (OTC Pink: BTAX) (“Biostax”), a hub and spoke biotech development engine, announces the appointment of Ms. Clay Caperton to its Board of...
Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment
24 oct. 2023 09h15 HE
|
Biostax Corp
ORLANDO, Fla., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Biostax Corp (OTC Pink: BTAX), a leading public company specializing in healthcare solutions, today announced a milestone in its transformative...
Biostax Corp Announces the Passing of Esteemed Director, H. Louis Salomonsky
14 sept. 2023 09h15 HE
|
Immune Therapeutics, Inc.
Orlando, FL, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp (OTC Pink: IMUN) (“Biostax”), a hub and spoke biotech development engine, sadly announces the passing of...
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV
29 août 2023 09h05 HE
|
Immune Therapeutics, Inc.
Orlando, FL, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp. (OTC Pink: IMUN) (“Biostax”), a hub-and-spoke biotech development engine, announces the signing of a...
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH
15 août 2023 09h05 HE
|
Immune Therapeutics, Inc.
Orlando, FL, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp. (OTC Pink: IMUN) ("Biostax"), a hub-and-spoke biotech development engine, announces that they have...
Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies
20 avr. 2023 09h05 HE
|
Immune Therapeutics, Inc.
Orlando, FL, April 20, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp. (OTC Pink: IMUN) (“Biostax”), a hub-and-spoke biotech development engine and Statera Biopharma...
Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction
01 mars 2023 09h34 HE
|
Immune Therapeutics, Inc.
ORLANDO, March 01, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" or "IMUN"), a specialty pharmaceutical company involved in the acquisition, development and...
Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development
09 nov. 2022 17h00 HE
|
Immune Therapeutics, Inc.
Orlando, FL, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”) today announced that its Chief Executive Officer, President, and Director, Stephen...